**Supporting Information:**

**Table of Contents**

|  |  |  |
| --- | --- | --- |
| **Page** | **Table number** | **Content** |
| 2-3 | - | Search strategy and selection criteria |
| 4-14 | Supplemental Table 1 | Characteristics of included studies for overall NAFLD prevalence analysis |
| 15-16 | Supplemental Table 2 | Characteristics of included studies for analysis of incidence of NAFLD in general population |
| 17-22 | Supplemental Table 3 | Quality assessment of studies included in prevalence and incidence analysis |
| 23 | Supplemental Table 4a | The prevalence of NAFLD in South Korea by province |
| 24 | Supplemental Table 4b | The prevalence of NAFLD in Seoul v. outside of Seoul |
| 25 | Supplemental Table 5 | Sensitivity analysis and Egger’s test for publication bias of NAFLD prevalence |
| 26 | Supplemental Table 6 | Sensitivity analysis of NAFLD incidence |
| 27 | Supplemental Figure 1 | Funnel plot and *P* value of Egger’s test for publication bias of NAFLD prevalence and incidence analysis in general population |
| 28-38 | - | References |

**1. Search strategy**

**PubMed, from inception to June 29, 2019 (498 articles)**

**Search terms:**

("nonalcoholic fatty liver" [tw] OR "non-alcoholic fatty liver" [tw] OR ("non-alcoholic" [ti] AND fatty [ti]) OR "non-alcoholic fatty liver disease" [mesh] OR (nonalcoholic [ti] AND

fatty [ti]) OR ((non-alcoholic [ti] OR nonalcoholic [ti]) AND "fatty liver" [mesh]) OR "nonalcoholic steatohepatitis" [tw] OR NAFLD [tw]) AND ( korean\* [tw] OR korea\* [tw] OR “south korea” [tw] OR “s korea” [tw] ) NOT ("randomized controlled trial" [pt] OR "controlled clinical trial" [pt] OR randomized [ti] OR "clinical trials as topic"[mesh] OR "clinical trial" [ti]

OR "clinical trials" [ti] OR "clinical trial" [pt]) NOT ("animals" [mesh] NOT "humans" [mesh]) NOT (mice [ti] OR rat [ti] OR rats [ti] OR murine [ti]) NOT (review [pt])

**Embase, from inception to June 29, 2019 (802 articles)**

**Search terms:**

('nonalcoholic fatty liver'/exp OR ('non-alcoholic':ti,ab,kw AND 'fatty liver':ti,ab,kw) OR 'nonalcoholic fatty liver' OR 'nonalcoholic fatty liver':ti,ab,kw OR 'nonalcoholic

steatohepatitis':ti,ab,kw OR NAFLD:ti,ab,kw) AND ('korean\*':ti,ab,kw OR 'korea\*':ti,ab,kw OR 'southkorea':ti,ab,kw OR 'skorea':ti,ab,kw) NOT ('randomized controlled trial'/exp OR

'randomized controlled trial' OR 'controlled clinical trial'/exp OR 'controlled clinical trial' OR 'randomized':ti OR 'clinical trial':ti OR 'clinical trials':ti) AND ([embase]/lim OR [embase

classic]/lim) AND [humans]/lim

**Cochrane library, from inception to June 29, 2019 (6 articles)**

**Search terms:**

("nonalcoholic fatty liver" OR "non-alcoholic fatty liver" OR (nonalcoholic AND fatty) OR "nonalcoholic steatohepatitis" OR NAFLD) AND (korean\* OR korea\* “South Korea” OR

“S Korea”)

**KoreaMed, from inception to June 29, 2019 (179 articles)**

**Search terms:**

("nonalcoholic fatty liver" OR "non-alcoholic fatty liver" OR (nonalcoholic AND fatty) OR "nonalcoholic steatohepatitis" OR NAFLD) AND (korean\* OR korea\* “South Korea” OR

“S Korea”)

**2. Selection criteria**

Inclusion criteria for original research articles were as follows: (1) NAFLD patients in South Korea; (2) NAFLD diagnosed by imaging (ultrasound, computed tomography scan, and magnetic resonance imaging/spectroscopy), liver biopsy, and/or blood testing/predictive indices (fatty liver index or hepatic steatosis index) or ICD codes; (3) the study was either a cross-sectional study or a baseline survey of longitudinal study; and (4) the study provided information about sample size and estimation of prevalence, incidence, or outcome (HCC or all-cause mortality) of NAFLD and/or of non-liver comorbidities on patients with NAFLD.

Exclusion criteria were as follows: (1) the study was a review article, clinical trial, animal study, case report or conference abstract; (2) the study did not identify patients with NAFLD; (3) the study was conducted in a pediatric population (<18 years); (4) the study did not exclude other causes of liver disease, such as viral hepatitis, etc.; (5) the study did not report screening for excess alcohol consumption; (6) the study was conducted in patients with severe comorbidities, such as human immunodeficiency virus (HIV), cancer, use of immunosuppressive therapies, and pregnant patients. If there were multiple studies from one cohort, we included data from the most recent report; if there was minimal overlap of the study period, then all associated studies were included. Collaborative studies with patients recruited from outside of South Korea were excluded.

**Supplemental Table 1:** Characteristics of included studies for overall NAFLD prevalence analysis

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference number** | **Author** | **Publication year** | **Study period** | **Study Population (n)** | **Mean age**  **(years)** | **Male (%)** | **Prevalence of NAFLD (%)** | **Characteristics of NAFLD patients** | | | **Referenced figures and tables** |
| **T2DM (%)** | **T2DM incidence**  **(per 1000 person years)** | **NASH**  **(%)** |
| 1 | Ahn, AL | 2013 | 5/1/2008 – 4/30/2010 | 1,706 | 57.9 | 55.0 | 32.0 | 58.1 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 3 | Ahn, JS | 2013 | - | 492 | 30.1 | 61.2 | 51.0 | - | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 5, Supplemental Figure 1 |
| 2\* | Ahn, JS | 2017 | 1/1/2003-12/31/2012 | 26,540 | 49.8 | 63.7 | 35.8 | - | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 5 | Bae, JC | 2010 | 1/1/2007-12/31/2008 | 99,969 | 40.1 | 59.6 | 28.1 | - | - | - | Table 1, Table 4, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 4 | Bae, JC | 2011 | 1/1/2005-12/31/2005 | 7,849 | - | 68.9 | 29.2 | - | - | - | Table 1, Table 4 |
| 6 | Bae, JC | 2012 | 1/1/2008-12/31/2008 | 72,359 | 42 | 53.9 | 27.5 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 8 | Bae, JC | 2017 | 1/1/2005-12/31/2005 | 7,849 | - | 0.01 | 29.2 | - | 25.4 | - | Table 1, Table 4, Table 5 |
| 7 | Bae, JC | 2018 | 1/1/2005-12/31/2009 | 7,849 | 44.6 | 68.9 | 46.7 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b |
| 9 | Baeg, MK | 2016 | 1/1/2010-12/31/2011 | 3,663 | - | 58.4 | 25.8 | - | - | - | Table 1, Table 5, Supplemental Table 5, Supplemental Figure 1 |
| 11\* | Baik, M | 2019 | 1/1/2014-12/31/2014 | 321 | - | 59.5 | 64.2 | 68.6 | - | - | Table 1, Table 4, Table 2, Table 3a |
| 10\* | Baik, M | 2019 | 1/1/2014-12/31/2014 | 395 | 65.5 | 59.5 | 41.5 | 50 | - | - | Table 1, Table 5, Table 2, Table 3a |
| 18 | Chang, Y | 2008 | 1/1/2002-12/31/2002 | 8,329 | 36.7 | 100 | 30.2 | - | - | - | Table 1, Table 4, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 14\* | Chang, Y | 2013 | 1/1/2005-12/31/2006 | 43,166 | 36.8 | 62.5 | 27.0 | 55.3 | - | - | Table 1, Table 4, Table 5, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 16\* | Chang, Y | 2016 | 1/1/2005-12/31/2013 | 74,509 | 36.2 | 41.9 | 8.8 | - | - | - | Table 1, Table 4, Supplemental Table 4a |
| 12\* | Chang, Y | 2019 | 1/1/2002-12/31/2014 | 388,809 | 39.2 | 49.5 | 25.1 | 55.8 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 5, Supplemental Figure 1 |
| 13\* | Chang, Y | 2019 | 1/1/2002-12/31/2017 | 86,911 | 40.6 | 74.4 | 39.6 | 73.1 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 5, Supplemental Figure 1 |
| 22 | Cho, HC | 2016 | 1/1/2014-4/30/2014 | 1,711 | 43.1 | 80.2 | 12.4 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 23 | Cho, HJ | 2019 | 1/1/2000-12/31/2000 | 2,726 | - | 57.6 | 30.3 | - | - | - | Table 1 |
| 24 | Cho, SH | 2008 | 4/1/2007-6/30/2007 | 198 | 44.9 | 41.9 | 14.6 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 25 | Choe, EY | 2017 | - | 5,507 | 56.8 | 50.9 | 46.4 | 46.4 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 26 | Choe, YG | 2013 | 1/1/2009-12/31/2009 | 9,162 | 41.9 | 55.2 | 27.9 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 27 | Choi, JH | 2013 | 1/1/2005-12/31/2005 | 7,849 | 44.6 | 68.9 | 29.2 | - | - | - | Table 1, Table 3a, Supplemental Table 4a, Supplemental Table 4b |
| 28 | Choi, SY | 2009 | 1/1/2006-12/31/2006 | 17,350 | 49.4 | 52.3 | 33.3 | 55.8 | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 29 | Choi, WG | 2010 | 4/1/2007-8/31/2009 | 3,106 | 46.1 | 71.9 | 22.3 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b |
| 30 | Choi, Y | 2016 | 3/1/2011-12/31/2013 | 100,177 | - | 46.5 | 21.8 | - | - | - | Table 1 |
| 31 | Chon, CW | 2012 | 1/1/2005-12/31/2005 | 1,161 | 44.8 | 100 | 9.2 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b |
| 32 | Chon, YE | 2016 | 11/1/2011-2/28/2013 | 340 | 56 | 56.2 | 45.9 | - | - | - | Table 1, Table 5, Supplemental Table 5, Supplemental Figure 1 |
| 35 | Chung, GE | 2015 | 1/1/2010-12/31/2010 | 1,423 | 52.4 | - | 20.7 | - | - | - | Table 1, Table 5 |
| 37\* | Chung, GE | 2015 | 1/1/2010-12/31/2013 | 2,954 | 55.8 | 64.7 | 42.3 | 59.1 | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 38 | Chung, GE | 2017 | 1/1/2005-12/31/2010 | 3,473 | - | - | 33.6 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 34 | Chung, GE | 2018 | 1/1/2014-12/31/2014 | 6,290 | 50.1 | 53.9 | 37.2 | - | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 36\* | Chung, GE | 2018 | 1/1/2010-12/31/2010 | 3,300 | 54.1 | 62.9 | 39.7 | 56.7 | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 33 | Chung, GE | 2019 | 5/1/2011-12/21/2011 | 1,190 | 51.5 | 42.1 | 27.8 | 54.8 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 39 | Huh, JH | 2015 | 11/1/2005-1/31/2008 | 1,521 | 53.5 | 31.8 | 8.2 | - | - | - | Table 1 |
| 40\* | Huh, JH | 2015 | 1/1/2008-12/31/2010 | 27,433 | 51.5 | - | 7.1 | - | - | - | Table 1, Table 5 Supplemental Table 5, Supplemental Figure 1 |
| 41 | Huh, JH | 2017 | 1/1/2001-12/31/2002 | 4,761 | 51.9 | 38.0 | 12.6 | 29.6 | - | - | Table 1, Table 3a, Table 5, Supplemental Table 5, Supplemental Figure 1 |
| 42\* | Huh, JH | 2017 | 4/1/2013-8/31/2014 | 2,198 | 53.7 | 55.7 | 54.0 | - | - | - | Table 1, Table 5, Table 2, Table 3, Supplemental Table 5, Supplemental Figure 1 |
| 43 | Hwang, ST | 2010 | 1/1/2007-12/31/2007 | 2,917 | 47.0 | 65.5 | 30.6 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 44 | Hwang, YC | 2018 | 1/1/2002-12/31/2012 | 318,224 | 39.3 | 51.9 | 26.1 | 62.8 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 5, Supplemental Figure 1 |
| 45 | Jang, EH | 2019 | 3/1/2011-12/31/2016 | 137,465 | - | - | 27.3 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 5, Supplemental Figure 1 |
| 46 | Jang, H | 2019 | 10/1/2008-12/31/2013 | 1,260 | 63.8 | 50.8 | 39.5 | 56.0 | - | - | Table 1, Table 5, Table 2, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 47 | Jang, HR | 2018 | 1/1/2003-12/31/2013 | 1,525 | 60.8 | 69.8 | 40.9 | 56.8 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 48 | Jeong, EH | 2013 | 1/1/2009-12/31/2010 | 141,610 | 41.6 | 57.2 | 27.3 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 5, Supplemental Figure 1 |
| 50 | Jun, DW | 2008 | - | 408 | 46.9 | 43.1 | 51.5 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b |
| 51 | Jun, DW | 2017 | 1/1/2000-12/31/2010 | 328 | 36.4 | 70.7 | - | 100 | - | - | Table 1, Table 5, Table 2, Table 3a, Table 3b |
| 52 | Jun, EJ | 2009 | 1/1/2006-12/31/2006 | 835 | 43.9 | - | 11.9 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b |
| 53\* | Jun, MJ | 2014 | 2/1/2001-4/30/2012 | 1,766 | 29 | 66.5 | 38.3 | - | - | 0 | Table 1, Table 2, Table 3a, Table 3b, Supplemental Table 5, Supplemental Figure 1 |
| 55 | Jung, CH | 2013 | 1/1/2007-12/31/2007 | 7,860 | 48.6 | 65.6 | 10.7 | - | 35.1 | - | Table 1, Table 4, Table 5, Supplemental Table 5, Supplemental Figure 1 |
| 54 | Jung, CH | 2016 | 3/1/2007-12/31/2013 | 34,258 | 47.4 | 58.0 | 33.8 | - | - | - | Table 1, Table 5 |
| 57 | Jung, JY | 2017 | 5/1/2011-12/31/2012 | 20,821 | 39.7 | 62.8 | 29.6 | 70.2 | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 5 |
| 58 | Kang, MK | 2015 | 1/1/2007-12/31/2010 | 772 | 49.2 | 68.0 | 44.8 | 64.4 | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 59 | Kang, YM | 2017 | 1/1/2007-6/30/2011 | 1,240 | 54.2 | 81.7 | 46.0 | - | - | - | Table 1, Table 5 Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 60 | Keum, SH | 2012 | 1/1/2005-12/31/2008 | 189 | 52.7 | 63.0 | 39.2 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 61\* | Khang, AR | 2019 | 1/1/2010-12/31/2011 | 10,107 | - | 38.3 | 11.2 | 26.4 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 5, Supplemental Figure 1 |
| 62 | Kim, BJ | 2016 | 1/1/2010-12/31/2011 | 1,472 | 44.1 | 84.3 | 45.9 | 74.0 | - | - | Table 1, Table 5, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 63 | Kim, CW | 2013 | 1/1/2011-12/31/2011 | 45,293 | 39.7 | 57.6 | 29.1 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 64 | Kim, D | 2012 | 10/1/2003-12/31/2008 | 4,023 | 56.8 | 60.7 | 40.2 | 53.3 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 69 | Kim, G | 2017 | 2/1/2012-12/31/2014 | 231 | 51.4 | 30.7 | 55.8 | 50.2 | - | - | Table 1, Table 5, Table 2, Table 3a |
| 68 | Kim, G | 2018 | 8/1/2006-8/1/2013 | 15,567 | 61.8 | 58.4 | 18.9 | 60.4 | - | - | Table 1, Table 5, Supplemental Table 5, Supplemental Figure 1 |
| 70 | Kim, GA | 2017 | 9/1/2004-12/31/2005 | 25.947 | 48.0 | 53.8 | 33.6 | 65.0 | - | - | Table 1, Table 4, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 71 | Kim, HJ | 2002 | 4/1/2001-6/30/2001 | 1,074 | 52 | 46.8 | 48.6 | 71.4 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 72\* | Kim, HJ | 2004 | 4/1/2001-6/30/2001 | 768 | 51.7 | 46.0 | 23.4 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b |
| 73 | Kim, HK | 2002 | 4/1/2000-6/30/2000 | 115 | 47.3 | 30.4 | 26.1 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 74 | Kim, HK | 2009 | 1/1/2000-12/31/2000 | 2,895 | 47 | 51.9 | 32.1 | - | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 75 | Kim, HL | 2011 | 1/1/2005-12/31/2009 | 794 | 65.4 | 69.4 | 39.0 | 48.3 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 76\* | Kim, HY | 2016 | 1/1/2010-12/31/2011 | 3,739 | 45.2 | 31.7 | 10.4 | 26.9 | - | - | Table 1, Table 5, Supplemental Table 5, Supplemental Figure 1 |
| 77 | Kim, J | 2017 | 1/1/2010-12/31/2010 | 1,575 | 39.9 | 89.6 | 46.6 | - | - | - | Table 1, Table 4, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 78 | Kim, JH | 2019 | - | 5,427 | - | 48.2 | 16.1 | - | - | - | Table 1, Supplemental Table 5, Supplemental Figure 1 |
| 79 | Kim, JK | 2012 | 1/1/1992-7/31/2008 | 64 | 22.2 | 100 | - | 100 | - | 46.9 | Table 1, Table 5, Table 2, Table 3a |
| 80 | Kim, JM | 2016 | 1/1/2012-12/31/2014 | 79 | - | 67.1 | 10.1 | - | - | - | Table 1 |
| 81 | Kim, JY | 2016 | 1/1/2004-12/31/2007 | 1,695 | 50.5 | 29.5 | 20.5 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 82\* | Kim, KM | 2012 | 10/1/1995-12/31/2009 | 1,365 | - | - | 59.7 | - | - | - | Table 1, Table 2, Table 3a, Supplemental Table 5, Supplemental Figure 1 |
| 83 | Kim, MK | 2015 | 1/1/2008-2/28/2013 | 919 | 57.6 | - | 32.0 | 0 | - | - | Table 1, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b |
| 85 | Kim, NH | 2014 | 1/1/2001-1/1/2007 | 2,307 | - | 41.5 | 36.1 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5 |
| 84 | Kim, NH | 2018 | 4/1/2011-12/31/2015 | 160,862 | 36.1 | 51.7 | 25.5 | - | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Figure 1 |
| 87 | Kim, S | 2013 | 5/1/2008-4/30/2010 | 759 | 56.8 | 51.3 | 12.9 | - | - | - | Table 1 |
| 86 | Kim, S | 2017 | 1/1/2002-12/31/2014 | 208,578 | 37.3 | 53.9 | 24.4 | 17.0 | - | - | Table 1, Table 5 |
| 88 | Kim, SH | 2011 | 1/1/2006-12/31/2007 | 5,083 | - | 50.2 | 38.2 | - | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 89\* | Kim, SH | 2014 | 5/26/2009-12/7/2010 | 1,886 | 56.6 | 37.8 | 22.3 | 45.5 | - | - | Table 1, Figure 4, Table 1, Supplemental Table 5, Supplemental Figure 1 |
| 90 | Kim, SM | 2006 | 5/1/2004-9/30/2004 | 208 | 53.2 | 63.5 | - | 0 | - | - | Table 1 |
| 91 | Kim, SS | 2018 | 1/1/2000-12/31/2000 | 2,920 | 45.5 | 57.9 | 31.6 | 59.9 | - | - | Table 1, Table 4, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 92 | Kim, SY | 2007 | 11/1/2003-1/31/2004 | 401 | 45.9 | 64.6 | 27.2 | 56.4 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 94 | Kim, YC | 2011 | 1/1/2003-12/31/2003 | 494 | 40.8 | 85.0 | 78.0 | - | - | - | Table 1, Table 5, |
| 95 | Kim, YS | 2013 | 1/1/2009-7/1/2011 | 108 | 39.0 | 67.6 | - | - | - | 62.0 | Table 1, Table 5, Table 2, Table 3a, Table 3b |
| 96 | Koo, BS | 2018 | 1/1/2013-1/1/2017 | 525 | 53.2 | 49.7 | - | 90.0 | - | 49.0 | Table 1, Table 5, Table 2, Table 3a |
| 97 | Kwak, MS | 2015 | 1/1/2010-12/31/2010 | 17,612 | 48.5 | 49.3 | 30.3 | 57.2 | - |  | Table 1, Table 5, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 99 | Kwak, MS | 2015 | 3/1/2007-12/31/2008 | 1,205 | 51.5 | 56.7 | 32.4 | 56.2 | - |  | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 98 | Kwak, MS | 2017 | 1/1/2007-12/31/2009 | 1,277 | 49.5 | 63.4 | 40.3 | 67.6 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 101\* | Kwak, MS | 2017 | 7/1/2011-7/1/2012 | 213 | 59 | 86.4 | 40.4 | 40.3 | - | - | Table 1, Table 5, Table 2 |
| 100\* | Kwak, MS | 2017 | 1/1/2010-12/31/2012 | 7,417 | 56.7 | - | 6.6 | - | - | - | Table 1, Table 5, Supplemental Table 5, Supplemental Figure 1 |
| 102 | Kwon, YM | 2012 | 1/1/2003-12/31/2010 | 30,044 | 45.3 | 34.4 | 20.1 | 0 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 103 | Lee, H | 2019 | 1/1/2002-12/31/2016 | 606 | - | 23.6 | 58.6 | 58.6 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 104 | Lee, HW | 2016 | 11/1/2011-12/31/2013 | 183 | 40.6 | 60.7 | - | - | - | 54.0 | Table 1, Table 5, Table 2, Table 3a, Table 3b |
| 105\* | Lee, HW | 2017 | 1/1/2011-7/31/2012 | 304 | 56.5 | 45.7 | 44.1 | 68.1 | - | - | Table 1, Table 3a, Table 5, Supplemental Table 5, Supplemental Figure 1 |
| 106 | Lee, HW | 2017 | 4/1/2013-8/31/2014 | 2,749 | - | 58.2 | 42.9 | 66.7 | - | - | Table 1, Table 5, Table 2, Supplemental Table 5, Supplemental Figure 1 |
| 108 | Lee, JA | 2004 | 91/2003-1/31/2004 | 60 | 43.9 | 36.7 | 30.0 | 0 | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b |
| 109 | Lee, JE | 2018 | 1/1/2007-7/31/2010 | 1,652 | 53.4 | 100 | 49.5 | 66.4 | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b |
| 110 | Lee, JI | 2016 | 1/1/2011-12/31/2012 | 15,913 | 46.3 | 75.7 | 42.4 | 70.0 | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 111\* | Lee, JY | 2007 | 7/1/2004-9/1/2005 | 589 | 31.2 | 69.3 | 51.4 | - | - | 4.3 | Table 1, Table 2, Table 3a, Table 3b, Supplemental Table 5, Supplemental Figure 1 |
| 112 | Lee, K | 2009 | 3/1/2005-6/30/2006 | 13,768 | - | 53.1 | 26.2 | 59.7 | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 113 | Lee, KE | 2002 | 4/1/2001-6/30/2001 | 779 | 53.2 | 35.1 | 47.5 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 116 | Lee, MK | 2015 | 1/1/2010-12/31/2011 | 21,335 | 40.8 | 100 | 47.2 | 71.6 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 117 | Lee, S | 2016 | 3/1/2007-3/1/2009 | 7,917 | 49.0 | 44.8 | 46.0 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 118 | Lee, SB | 2018 | 1/1/2007-12/31/2011 | 5,121 | 53.8 | 68.1 | 38.6 | 57.1 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 120 | Lee, T | 2016 | 1/1/2010-12/31/2011 | 44,220 | 42.6 | 70.7 | 33.1 | 62.8 | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 5, Supplemental Figure 1 |
| 122 | Lee, YH | 2014 | 1/1/2008-12/31/2010 | 15,676 | 47.9 | 53.0 | 41.2 | 72.8 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 123\* | Lee, YH | 2015 | 1/1/2008-12/31/2011 | 15,132 | 50.6 | 37.1 | 21.8 | - | - | - | Table 1, Table 5, Supplemental Table 5, Supplemental Figure 1 |
| 124\* | Lee, YH | 2016 | 1/1/2008-12/31/2011 | 2,761 | 55.8 | 44.9 | - | 100 | - | - | Table 1, Table 5, Table 2 |
| 125 | Lee, YI | 2012 | 7/1/2002-6/30/2006 | 5,517 | 46.8 | - | 15.1 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 126 | Lee, YJ | 2010 | 3/1/2006-5/1/2007 | 3,768 | 46.1 | 56.6 | 25.8 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 131 | Oh, SY | 2006 | 1/1/2004-12/31/2004 | 40,196 | - | 61.9 | 26.7 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 119 | Lee, SY | 2008 | 7/24/2006-9/30/2006 | 360 | 42.8 | 41.7 | 20.0 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 127 | Min, YW | 2012 | 1/1/2000-12/31/2005 | 227 | 60.9 | 70.9 | 26.0 | 31.1 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 128 | Moon, JS | 2013 | 1/1/2009-12/31/2011 | 9,565 | 47.0 | 55.3 | 19.3 | - | - | - | Table 1, Supplemental Table 5, Supplemental Figure 1 |
| 129\* | Nah, EH | 2008 | 1/1/2006-12/31/2006 | 7,150 | 46.9 | 31.8 | 33.3 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 130 | Nam, JS | 2016 | 1/1/2007-2/28/2013 | 2,242 | 52.9 | 64.4 | 43.5 | 0 | - | - | Table 1, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b |
| 132 | Park, BJ | 2008 | 1/1/1998-12/31/2005 | 177 | 32.6 | 69.5 | 29.4 | 0 | - | - | Table 1, Table 2, Table 3a |
| 133 | Park, D | 2015 | 1/1/2008-12/31/2015 | 7,514 | 53.0 | 70.2 | 41.3 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 134 | Park, HE | 2016 | 11/1/2003-12/31/2013 | 1,732 | 57.2 | 74.4 | 48.8 | 66.1 | - | - | Table 1, Table 5, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 135 | Park, JH | 2015 | 11/1/2009-6/30/2012 | 1,363 | 49 | 100 | 44.2 | - | - | - | Table 1, Figure 4, Table 4, Supplemental Table 4a, Supplemental Table 4b |
| 136 | Park, JM | 2019 | 11/1/2013-7/1/2015 | 613 | 53.6 | - | 28.2 | 60.9 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 137 | Park, JW | 2007 | - | 39 | 32.8 | 76.9 | - | 100 | - | 61.5 | Table 1, Table 5, Table 2, Table 3a, Table 3b |
| 138 | Park, KS | 2004 | 1/1/1998-12/31/2002 | 43 | 32.9 | 79.1 | ­- | 100 | - | 79.1 | Table 1, Table 5, Table 2, Table 3a, Table 3b |
| 139 | Park, SH | 2003 | 1/5/2002-5/31/2002 | 239 | - | 62.4 | 10.8 | - | - | - | Table 1, Supplemental Table 4b, Supplemental Table 5, Supplemental Ta Figure 1ble 7 |
| 140 | Park, SH | 2006 | 1/1/2003-12/31/2003 | 5,228 | 47.9 | 46.9 | 23.7 | 34.8 | - | - | Table 1, Table 5, Supplemental Table 5, Supplemental Figure 1 |
| 141 | Park, SK | 2013 | 1/1/2005-12/31/2010 | 25,232 | 42.5 | 35.1 | 35.1 | 0 | - | - | Table 1, Table 4, Table 5 |
| 143 | Rhee, EJ | 2013 | 1/1/2010-12/31/2010 | 6,567 | 42 | 100 | 43.6 | 0 | - | - | Table 1, Table 5 |
| 146\* | Ryoo, JH | 2013 | 1/1/2005-12/31/2005 | 11,926 | 44.1 | 100 | 29.3 | 51.5 | - | - | Table 1, Table 5, Table 2, Table 3a |
| 144\* | Ryoo, JH | 2014 | 1/1/2005-12/31/2005 | 11,350 | 41.4 | 100 | 29.7 | 57.9 | - | - | Table 1, Table 4, Table 2, Table 5, Table 3a |
| 145\* | Ryoo JH | 2014 | 1/1/2005-12/31/2005 | 22,090 | 42.1 | 100 | 34.2 | 64.7 | - | - | Table 1, Table 5, Table 4, Table 2, Table 3a, Supplemental Table 4a |
| 147\* | Ryoo, JH | 2016 | 1/1/2005-12/31/2005 | 20,628 | 42.7 | 100 | 28.5 | 0 | - | - | Table 1, Table 4, Table 2, Table 5, Table 3a |
| 148\* | Ryu, S | 2015 | 3/1/2011-12/31/2013 | 139,056 | 39.9 | 52.4 | 28.2 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 5, Supplemental Figure 1 |
| 149 | Ryu, S | 2015 | 11/1/2012-4/30/2013 | 1,559 | 48.9 | \_ | 21.4 | 72.9 | - | - | Table 1, Table 5, Supplemental Table 4a |
| 151 | Seo, HI | 2012 | 1/1/2007-12/31/2007 | 1,365 | 48.4 | 71.6 | 54.4 | - | - | - | Table 1, Table 5 |
| 152 | Seo, NK | 2015 | 1/1/2006-12/31/2009 | 1,994 | - | 100 | 43.2 | 55.7 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 153 | Seo, SH | 2006 | 1/1/1997-6/30/2003 | 23,762 | 46.6 | 51.2 | 11.5 | 32.7 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 155 | Shin, JY | 2015 | 4/1/2009-3/30/2011 | 16,592 | 47.9 | 40.9 | 28.1 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 156 | Shin, WY | 2011 | 7/1/2007-6/30/2008 | 628 | 46.2 | 52.1 | 58.6 | 0 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 162 | Sinn, DH | 2012 | 1/1/2009-12/31/2009 | 5,878 | 48.4 | 39.2 | 27.4 | 0 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 157 | Sinn, DH | 2015 | 1/1/2009-12/31/2009 | 7,067 | 50.1 | - | 27.5 | - | - | - | Table 1, Table 5 |
| 160\* | Sinn, DH | 2016 | 1/1/2005-12/31/2013 | 37,799 | 51.5 | 86.1 | 41.4 | - | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 161\* | Sinn, DH | 2016 | 1/1/2005-12/31/2013 | 8,020 | 49.2 | 100 | 39.7 | - | - | - | Table 1, Table 4, Table 2, Table 5, Table 3a |
| 158\* | Sinn, DH | 2017 | 1/1/2003-12/31/2013 | 41,430 | 48.9 | 60.9 | 34.3 | 63.4 | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 159\* | Sinn, DH | 2017 | 1/1/2004-12/31/2013 | 4,731 | 52.2 | 91.0 | 44.1 | 63.5 | - | - | Table 1, Table 4, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 163 | Song, DS | 2019 | 1/1/2011-12/31/2015 | 665 | 51.5 | 73.1 | - | 100 | - | - | Table 1, Table 5 |
| 165 | Song, YA | 2016 | 1/1/2012-12/31/2014 | 1,943 | 51.8 | 100 | 52.8 | - | - | - | Table 1, Table 5, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b |
| 174 | Sung, KC | 2007 | 1/1/2005-12/31/2005 | 36,654 | 41 | 53.5 | 24.6 | 0 | - | - | Table 1, Table 2, Table 3a, Supplemental Table 4a, Supplemental Table 4b |
| 175 | Sung, KC | 2009 | 1/1/2005-12/31/2005 | 30,172 | 41 | 44.7 | 23.5 | 69.2 | - | 59.7 | Table 1, Table 5, Table 3a |
| 171\* | Sung, KC | 2011 | 1/1/2003-12/31/2003 | 11,091 | 40.9 | 41.7 | 26.8 | 0 | 8.2 | - | Table 1, Table 4, Table 5 |
| 166\* | Sung, KC | 2012 | 1/1/2003-12/31/2003 | 12,853 | 41.7 | 71.7 | 27.7 | 0 | 8.7 | - | Table 1, Table 4, Table 5 |
| 169 | Sung, KC | 2012 | 1/1/2010-12/31/2010 | 10,153 | 41.9 | 76.3 | 37.3 | - | 8.9 | - | Table 1, Table 5 |
| 175\* | Sung, KC | 2013 | 1/1/2003-12/31/2003 | 13,218 | 41.0 | 71.8 | 27.7 | 0 | - | - | Table 1, Table 2, Table 4, Supplemental Table 4a, Supplemental Table 4b |
| 167 | Sung, KC | 2014 | 1/1/2010-12/31/2010 | 14,384 | 42.0 | 82.5 | 43.5 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 172\* | Sung, KC | 2014 | 1/1/2003-12/31/2003 | 11,448 | 40.6 | 69.4 | 25.8 | - | - | - | Table 1, Table 4, Table 5 |
| 168 | Sung, KC | 2016 | 1/1/2010-12/31/012 | 2,175 | 42.5 | 95.1 | 52.5 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 173 | Sung, KC | 2018 | 1/1/2007-12/31/2014 | 29,386 | 36.1 | 81.8 | 57.3 | 0 | - | - | Table 1, Table 5, Supplemental Table 4a |
| 177 | Sung, KC | 2019 | 1/1/2002-12/31/2014 | 158,638 | - | \_ | 25.1 | - | - | - | Table 1 |
| 179 | Yadav, D | 2016 | 11/1/2005-1/31/2008 | 2,784 | 54.8 | 33.9 | 12.0 | 0 | 28.6 | - | Table 1, Table 4 |
| 181 | Yang, MH | 2016 | 1/1/2008-12/31/2010 | 8,327 | 52.9 | 18.8 | 27.1 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b |
| 180 | Yang, HJ | 2016 | 1/1/2002-12/31/2014 | 117,377 | 38.5 | 56.5 | 25.1 | 63.1 | - | - | Table 1, Table 5 |
| 182 | Yang, YJ | 2017 | 1/1/2009-12/31/2013 | 1,023 | 54.6 | 51.1 | 43.1 | 59.9 | - | - | Table 1, Table 5, Supplemental Table 5, Supplemental Figure 1 |
| 183 | Yeo, J | 2012 | 1/1/2010-6/30/2010 | 948 | 45.8 | 66.8 | 12.2 | - | - | - | Table 1, Table 5, Supplemental Table 4b |
| 184 | Yi, KH | 2017 | 1/1/2007-12/31/2009 | 4,387 | 35.5 | - | 15.4 | - | - | - | Table 1, Table 5 |
| 185 | Yoo, JH | 2019 | 1/1/2007-12/31/2007 | 14,465 | 48 | 59.5 | 32.0 | 0 | - | - | Table 1, Supplemental Table 4a |
| 186 | You, SC | 2015 | 1/1/2012-7/31/2012 | 159 | 56 | 54.7 | - | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 187\* | You, SC | 2015 | 1/1/2013-3/30/2014 | 285 | - | 56.5 | 49.8 | 68.2 | - | - | Table 1, Table 5, Supplemental Table 5, Supplemental Figure 1 |
| 188 | Yu, SJ | 2015 | 7/1/2000-8/31/2014 | 456 | 34.8 | 65.6 | - | 79.4 | - | 80.6 | Table 1, Table 5, Table 2, Table 3a, Table 3b |
| 190 | Yun, Y | 2019 | 6/1/2014-9/30/2014 | 268 | 43.6 | 51.5 | 28.4 | - | - | - | Table 1, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |
| 191 | Ze, EY | 2018 | 1/1/2008-12/31/2013 | 2,976 | 50 | 64.5 | 50.8 | - | - | - | Table 1, Table 5, Supplemental Table 4a, Supplemental Table 4b, Supplemental Table 5, Supplemental Figure 1 |

\* Studies that have similar cohorts but had differing inclusion/exclusion criterias

**Supplemental Table 2:** Characteristics of included studies for analysis of incidence of NAFLD in general population


|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference number** | **Author** | **Publication**  **year** | **Patients without NAFLD at baseline (n)** | **Mean age At Baseline (yrs)** | **Male (n, %)** | **New NAFLD (n)** | **Total follow-up (years)** | **Incidence (per 1000 person years)** | **Referenced in figures & tables:** |
| 17\* | Chang, Y | 2007 | 5,237 | 37 | 5,237, 100 | 984 | 3 | 74.1 | Figure 2, Table 4 |
| 20\* | Chang, Y | 2009 | 4,246 | 37 | 4,246, 100 | 622 | 4 | 37.0 | Figure 2, Table 4 |
| 15\* | Chang, Y | 2012 | 2,599 | 36 | 2,599, 100 | 651 | 7 | 50.0 | Figure 2, Table 4 |
| 19\* | Chang, Y | 2012 | 5,900 | 37 | 5,900, 100 | 1,938 | 7 | 69.0 | Figure 2, Table 4, Supplemental Table 6, Supplemental Figure 1 |
| 21 | Chang, Y | 2016 | 77,425 | 36 | 30,505, 39 | 10,340 | 11 | 29.7 | Figure 2, Table 4, Supplemental Table 6, Supplemental Figure 1 |
| 45 | Jang EH | 2019 | 137,465 | - | 40,018, 43 | 15,899 | - | 48.4 | Figure 2, Supplemental Table 6, Supplemental Figure 1 |
| 22 | Cho, HJ | 2019 | 1,901 | 44 | 991, 52 | 498 | 10 | - | Figure 2, Table 4, Supplemental Table 6, Supplemental Figure 1 |
| 38 | Chung, GE | 2017 | 2,216 | 48 | 955, 43 | 565 | 5 | 51.0 | Figure 2 |
| 49 | Joo, EJ | 2017 | 83,339 | 37 | 42,483, 51 | 22,932 | 8 | 47.3 | Figure 2, Table 4, Supplemental Table 6, Supplemental Figure 1 |
| 56 | Jung, HS | 2019 | 353,609 | 36 | 87,677, 44 | 45,409 | 2-7 | 42.4 | Figure 2, Table 4, Supplemental Table 6, Supplemental Figure 1 |
| 64 | Kim, CW | 2012 | 2,410 | 37 | 2,410, 100 | 586 | 4 | 77.7 | Figure 2, Table 4, Supplemental Table 6, Supplemental Figure 1 |
| 66\* | Kim, D | 2016 | 2,017 | - | 709, 52 | 288 | 5 | 47.3 | Figure 2, Table 4 |
| 67\* | Kim, D | 2018 | 956 | - | 351, 55 | 145 | 5 | 48.7 | Figure 2, Table 4 |
| 74 | Kim, HK | 2009 | 2,895 | 45 | 834, 43 | 374 | 5 | 38.6 | Figure 2, Table 4, Supplemental Table 6, Supplemental Figure 1 |
| 68 | Kim, G | 2018 | 15,567 | 51 | - | 1,864 | 7 | 21.1 | Figure 2, Supplemental Table 6, Supplemental Figure 1 |
| 85 | Kim, NH | 2014 | 2,307 | 50 | 397, 34 | 199 | 6 | 72.2 | Figure 2, Table 4 |
| 93\* | Kim, TJ | 2017 | 17,028 | 49 | 8,787, 52 | 3,381 | 8 | 40.7 | Figure 2, Supplemental Table 6, Supplemental Figure 1 |
| 107\* | Lee, J | 2017 | 4,138 | 37 | 4,138, 100 | 1,191 | 7 | 21.8 | Figure 2, Table 4 |
| 114 | Lee, KW | 2015 | 18,544 | 38 | 9,878, 53 | 2,348 | 4 | 43.7 | Figure 2, Table 4, Supplemental Table 6, Supplemental Figure 1 |
| 115 | Lee, MJ | 2019 | 9,782 | 46 | 2,174, 49 | 591 | 8-12 | 13.4 | Figure 2, Table 4 |
| 121 | Lee, WY | 2015 | 3,045 | 44 | 1,625, 53 | 490 | 4 | 40.2 | Figure 2, Table 4, Supplemental Table 6, Supplemental Figure 1 |
| 142\* | Rhee, EJ | 2011 | 4,954 | 40 | 2,502, 51 | 644 | 5 | 26.0 | Figure 2, Table 4 |
| 150\* | Ryu, S | 2011 | 5,741 | 37 | 5,741, 100 | 1,717 | 5 | 71.6 | Figure 2, Table 4 |
| 152 | Seo, NK | 2015 | 1,994 | 44 | 1,082, 100 | 242 | 4 | 53.3 | Figure 2, Table 4 |
| 154 | Seo, YY | 2013 | 363 | 41 | 210, 58 | 106 | 4 | 73.0 | Figure 2, Table 4, Supplemental Table 6, Supplemental Figure 1 |
| 161\* | Sinn, DH | 2016 | 8,020 | 49 | 4,835, 100 | 4835 | 8 | 70.1 | Figure 2, Table 4 |
| 164 | Song, JU | 2019 | 126,282 | 36 | 45,889, 45 | 25,525 | 13 | 44.0 | Figure 2, Table 4, Supplemental Table 6, Supplemental Figure 1 |
| 170 | Sung, KC | 2016 | 126,811 | 37 | 59,584, 47 | 29,014 | 12 | 46.2 | Figure 2, Table 4, Supplemental Table 6, Supplemental Figure 1 |
| 175\* | Sung, KC |  | 13,218 | - | 9,484, 99 | 1,640 | 5 | 34.3 | Figure 2, Supplemental Table 6, Supplemental Figure 1 |
| 167\* | Sung, KC | 2014 | 11,448 | 40 | 5,281, 62 | 1,418 | 5 | 33.4 | Figure 2, Table 4 |
| 178 | Sung, KC | 2012 | 2,589 | 46 | 1,305, 50 | 430 | 4~5 | 37.7 | Figure 2, Table 4, Supplemental Figure 1 |
| 189 | Yun, KE | 2016 | 37,130 | 39 | 17,209, 41 | 6,249 | 11 | 49.1 | Figure 2, Table 4, Supplemental Figure 1 |

\* Studies that have similar cohorts but had differing inclusion/exclusion criterias

**Supplemental table 3:** Quality assessment of studies included in prevalence and incidence analysis

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference number** | **Author** | **Publication year** | **Representativeness (0,1,2)** | **Sample size**  **0,1)** | **NAFLD as outcome of interest (0,1,2)** | **Comparability of study population (0,2)** | **Outcome assessment (0,1)** | **Statistical test (0,1)** | **Total** |
| 1 | Ahn AL | 2013 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 2 | Ahn JS | 2017 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 3 | Ahn JS | 2013 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 4 | Bae JC | 2011 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 5 | Bae JC | 2010 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 6 | Bae JC | 2012 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 7 | Bae JC | 2018 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 8 | Bae JC | 2017 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 9 | Baeg MK | 2016 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 10 | Baik M | 2019 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 11 | Baik M | 2019 | 2 | 0 | 2 | 0 | 1 | 1 | 6 |
| 12 | Chang Y | 2019 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 13 | Chang Y | 2019 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 14 | Chang Y | 2013 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 15 | Chang Y | 2012 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 16 | Chang Y | 2016 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 17 | Chang Y | 2007 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 18 | Chang Y | 2008 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 19 | Chang Y | 2012 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 20 | Chang Y | 2009 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 21 | Chang Y | 2016 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 22 | Cho HC | 2016 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 23 | Cho HJ | 2019 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 24 | Cho SH | 2008 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 25 | Choe EY | 2017 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 26 | Choe YG | 2013 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 27 | Choi JH | 2013 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 28 | Choi SY | 2009 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 29 | Choi WG | 2010 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 30 | Choi Y | 2016 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 31 | Chon CW | 2012 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 32 | Chon YE | 2016 | 2 | 0 | 2 | 0 | 1 | 1 | 6 |
| 33 | Chung GE | 2019 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 34 | Chung GE | 2018 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 35 | Chung GE | 2015 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 36 | Chung GE | 2018 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 37 | Chung GE | 2015 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 38 | Chung GE | 2017 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 39 | Huh JH | 2015 | 1 | 1 | 1 | 0 | 1 | 1 | 5 |
| 40 | Huh JH | 2015 | 1 | 1 | 1 | 0 | 1 | 1 | 5 |
| 41 | Huh JH | 2017 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 42 | Huh JH | 2017 | 1 | 1 | 1 | 0 | 1 | 1 | 5 |
| 43 | Hwang ST | 2010 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 44 | Hwang YC | 2018 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 45 | Jang EH | 2019 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 46 | Jang H | 2019 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 47 | Jang HR | 2018 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 48 | Jeong EH | 2013 | 1 | 1 | 2 | 2 | 1 | 1 | 8 |
| 49 | Joo EJ | 2017 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 50 | Jun DW | 2008 | 1 | 0 | 2 | 2 | 1 | 1 | 7 |
| 51 | Jun DW | 2017 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 52 | Jun EJ | 2009 | 2 | 0 | 2 | 0 | 1 | 1 | 6 |
| 53 | Jun MJ | 2014 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 54 | Jung CH | 2013 | 1 | 1 | 1 | 0 | 1 | 1 | 5 |
| 55 | Jung CH | 2016 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 56 | Jung HS | 2019 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 57 | Jung JY | 2017 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 58 | Kang MK | 2015 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 59 | Kang YM | 2017 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 60 | Keum SH | 2012 | 2 | 0 | 2 | 0 | 1 | 1 | 6 |
| 61 | Khang AR | 2019 | 2 | 1 | 1 | 0 | 1 | 1 | 6 |
| 62 | Kim BJ | 2016 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 63 | Kim CW | 2013 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 64 | Kim CW | 2012 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 65 | Kim D | 2012 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 66 | Kim D | 2016 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 67 | Kim D | 2018 | 2 | 0 | 2 | 0 | 1 | 1 | 6 |
| 68 | Kim G | 2018 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 69 | Kim G | 2017 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 70 | Kim GA | 2017 | 1 | 1 | 2 | 2 | 1 | 1 | 8 |
| 71 | Kim HJ | 2002 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 72 | Kim HJ | 2004 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 73 | Kim HK | 2002 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 74 | Kim HK | 2009 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 75 | Kim HL | 2011 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 76 | Kim HY | 2016 | 1 | 1 | 1 | 2 | 1 | 1 | 7 |
| 77 | Kim J | 2017 | 1 | 1 | 2 | 2 | 1 | 1 | 8 |
| 78 | Kim JH | 2019 | 1 | 1 | 1 | 0 | 1 | 1 | 5 |
| 79 | Kim JK | 2012 | 1 | 1 | 1 | 0 | 1 | 1 | 5 |
| 80 | Kim JM | 2016 | 1 | 1 | 1 | 0 | 1 | 1 | 5 |
| 81 | Kim JY | 2016 | 1 | 1 | 2 | 2 | 1 | 1 | 8 |
| 82 | Kim KM | 2012 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 83 | Kim MK | 2015 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 84 | Kim NH | 2018 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 85 | Kim NH | 2014 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 86 | Kim S | 2017 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 87 | Kim S | 2013 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 88 | Kim SH | 2011 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 89 | Kim SH | 2014 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 90 | Kim SM | 2006 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 91 | Kim SS | 2018 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 92 | Kim SY | 2007 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 93 | Kim TJ | 2017 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 94 | Kim YC | 2011 | 2 | 0 | 2 | 0 | 1 | 1 | 6 |
| 95 | Kim YS | 2013 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 96 | Koo, BK | 2018 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 97 | Kwak MS | 2015 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 98 | Kwak MS | 2018 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 99 | Kwak MS | 2015 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 100 | Kwak MS | 2018 | 1 | 1 | 1 | 2 | 1 | 1 | 7 |
| 101 | Kwak MS | 2015 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 102 | Kwon YM | 2012 | 1 | 1 | 2 | 2 | 1 | 1 | 8 |
| 103 | Lee H | 2019 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 104 | Lee HW | 2016 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 105 | Lee HW | 2017 | 1 | 1 | 1 | 0 | 1 | 1 | 5 |
| 106 | Lee HW | 2017 | 1 | 0 | 2 | 2 | 1 | 1 | 7 |
| 107 | Lee J | 2017 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 108 | Lee JA | 2004 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 109 | Lee JE | 2018 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 110 | Lee JI | 2016 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 111 | Lee JY | 2007 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 112 | Lee K | 2009 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 113 | Lee KE | 2002 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 114 | Lee KW | 2015 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 115 | Lee MJ | 2019 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 116 | Lee MK | 2015 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 117 | Lee S | 2016 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 118 | Lee SB | 2018 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 119 | Lee SY | 2008 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 120 | Lee T | 2016 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 121 | Lee WY | 2015 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 122 | Lee YH | 2014 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 123 | Lee YH | 2015 | 2 | 1 | 1 | 2 | 1 | 1 | 8 |
| 124 | Lee YH | 2016 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 125 | Lee YI | 2012 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 126 | Lee YJ | 2010 | 1 | 1 | 2 | 2 | 1 | 1 | 8 |
| 127 | Min YW | 2012 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 128 | Moon JS | 2013 | 1 | 1 | 1 | 0 | 1 | 1 | 5 |
| 129 | Nah EH | 2008 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 130 | Nam JS | 2016 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 131 | Oh SY | 2006 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 132 | Park BJ | 2008 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 133 | Park D | 2017 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 134 | Park HE | 2016 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 135 | Park JH | 2015 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 136 | Park JM | 2019 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 137 | Park JW | 2007 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 138 | Park KS | 2004 | 1 | 0 | 2 | 0 | 1 | 1 | 5 |
| 139 | Park SH | 2003 | 1 | 2 | 2 | 0 | 1 | 1 | 7 |
| 140 | Park SH | 2006 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 141 | Park SK | 2013 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 142 | Rhee EJ | 2011 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 143 | Rhee EJ | 2013 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 144 | Ryoo JH | 2014 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 145 | Ryoo JH | 2014 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 146 | Ryoo JH | 2013 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 147 | Ryoo JH | 2016 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 148 | Ryu S | 2015 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 149 | Ryu S | 2015 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 150 | Ryu S | 2011 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 151 | Seo HI | 2012 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 152 | Seo NK | 2015 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 153 | Seo SH | 2006 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 154 | Seo YY | 2013 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 155 | Shin JY | 2015 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 156 | Shin WY | 2011 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 157 | Sinn DH | 2015 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 158 | Sinn DH | 2017 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 159 | Sinn DH | 2017 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 160 | Sinn DH | 2016 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 161 | Sinn DH | 2016 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 162 | Sinn DH | 2012 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 163 | Song DS | 2019 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 164 | Song JU | 2019 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 165 | Song YA | 2016 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 166 | Sung KC | 2012 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 167 | Sung KC | 2014 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 168 | Sung KC | 2016 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 169 | Sung KC | 2012 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 170 | Sung KC | 2016 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 171 | Sung KC | 2011 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 172 | Sung KC | 2014 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 173 | Sung KC | 2018 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 174 | Sung KC | 2007 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 175 | Sung KC | 2013 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 176 | Sung KC | 2009 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 177 | Sung KC | 2019 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 178 | Sung KC | 2012 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 179 | Yadav D | 2016 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 180 | Yang HJ | 2017 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 181 | Yang MH | 2016 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 182 | Yang YJ | 2017 | 1 | 1 | 2 | 0 | 1 | 1 | 6 |
| 183 | Yeo J | 2012 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 184 | Yi KH | 2017 | 2 | 1 | 2 | 2 | 1 | 1 | 9 |
| 185 | Yoo JH | 2019 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 186 | You SC | 2015 | 2 | 0 | 2 | 0 | 1 | 1 | 6 |
| 187 | You SC | 2015 | 2 | 0 | 1 | 0 | 1 | 1 | 5 |
| 188 | Yu SJ | 2015 | 1 | 0 | 2 | 0 | 0 | 1 | 4 |
| 189 | Yun KE | 2016 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| 190 | Yun Y | 2019 | 2 | 0 | 2 | 2 | 1 | 1 | 8 |
| 191 | Ze EY | 2018 | 2 | 1 | 2 | 0 | 1 | 1 | 7 |

**Supplemental Table 4a:** The prevalence of NAFLD in South Korea by province



|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Region** | **Studies**  **(N)** | **Participants**  **(n)** | **Prevalence of NAFLD (%, 95% CI)** | **I2** | ***P* value** |
| **Whole country** | **1** | **2,440,289** | **34.23% (33.61 – 34.86)** | **0%** | **0.0081** |
| Gyeonggi-do | 98 | 2,377,934 | 33.10% (30.78 – 35.50) | 99.9% |  |
| Gangwon-do | 0 | 0 | - | - |  |
| Chungcheong-do | 0 | 0 | - | - |  |
| Jeolla-do | 0 | 0 | - | - |  |
| Gyeongsang-do | 5 | 40,265 | 18.19% (11.29 – 27.98) | 99.7% |  |

**Supplemental Table 4b.** The prevalence of NAFLD in Seoul v. outside of Seoul



|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Region** | **Studies**  **(N)** | **Participants**  **(n)** | **Prevalence of NAFLD (%, 95% CI)** | **I2** | ***P* value** |
| **Seoul vs. outside of Seoul** |  |  |  |  | 0.01 |
| Seoul | 76 | 798,300 | 34.55% (32.00 – 37.19) | 99.8% |  |
| Outside of Seoul | 14 | 71,239 | 25.22% (19.17 – 32.42) | 99.7% |  |

**Supplemental Table 5:** Sensitivity analysis and Egger’s test for publication bias of NAFLD prevalence

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Subgroup of sensitivity analysis** | **Studies**  **(N)** | **Study population (n)** | **NAFLD**  **(n)** | **Prevalence**  **(% 95% CI)** | **Egger’s test for publication bias**  ***P*-value (P)** |
| All studies | 85 | 2,062,833 | 571,645 | 31.46 (28.61 – 34.45) | 0.04 |
| Quality assessment score ≥7 | 34 | 1,160,275 | 324,981 | 27.87 (24.09 – 31.99) | 0.55 |
| Sample size ≥1000 | 71 | 2,057,020 | 569,159 | 30.45 (27.40 – 33.67) | 0.08 |
| Health check-up center studies | 74 | 2,010,152 | 561,422 | 32.68 (30.01 – 32.68) | 0.01 |
| Clinical clinic and survey data based studies | 11 | 52,681 | 10,223 | 24.06 (15.02 – 36.22) | 0.94 |
| Prevalence 10-50% | 77 | 2,018,188 | 563,984 | 30.97 (28.44 – 33.61) | 0.03 |

\*All I2 ≥99.8

**Supplemental Table 6:** Sensitivity analysis of NAFLD incidence

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Subgroup of sensitivity analysis** | **Studies (n)** | **NAFLD free participants (n)** | **New NAFLD (n)** | **Incidence (% 95% CI) (per 1000 person-years)** |
| All studies | 18 | 796,189 | 169,023 | 04.28 (03.86 – 04.71) |
| Quality assessment score ≥7 | 15 | 694,851 | 150,812 | 04.21 (03.76 – 04.68) |
| Sample size ≥1000 | 18 | 796,189 | 169,023 | 04.28 (03.86 – 04.71) |
| Health check-up center studies | 18 | 796,189 | 169,023 | 04.28 (03.86 – 04.71) |

\*All I2 ≥99.7

**Supplemental Figure 1:** Funnel plot and *P*-value of Egger’s test for publication bias of NAFLD prevalence and incidence analysis in general population

1. NAFLD prevalence analysis

A screenshot of a cell phone

Description automatically generated

*p*=0.039

B. NAFLD incidence analysis

A screenshot of a cell phone

Description automatically generated

*p*=0.619

References:

1. Ahn AL, Choi JK, Kim MN, Kim SA, Oh EJ, Kweon HJ, et al. Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older. Korean J Fam Med. 2013;34(3):199-205.

2. Ahn JS, Sinn DH, Min YW, Hong SN, Kim HS, Jung SH, et al. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther. 2017;45(2):345-53.

3. Ahn JS, Sinn DH, Gwak GY, Kim JM, Kwon CH, Joh JW, et al. Steatosis among living liver donors without evidence of fatty liver on ultrasonography: potential implications for preoperative liver biopsy. Transplantation. 2013;95(11):1404-9.

4. Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care. 2011;34(3):727-9.

5. Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, et al. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol. 2010;105(11):2389-95.

6. Bae JC, Suh S, Park SE, Rhee EJ, Park CY, Oh KW, et al. Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. PLoS One. 2012;7(10):e46819.

7. Bae JC, Han JM, Cho JH, Kwon H, Park SE, Park CY, et al. The persistence of fatty liver has a differential impact on the development of diabetes: The Kangbuk Samsung Health Study. Diabetes Res Clin Pract. 2018;135:1-6.

8. Bae JC, Kim SK, Han JM, Kwon S, Lee DY, Kim J, et al. Additive effect of non-alcoholic fatty liver disease on the development of diabetes in individuals with metabolic syndrome. Diabetes Res Clin Pract. 2017;129:136-43.

9. Baeg MK, Yoon SK, Ko SH, Noh YS, Lee IS, Choi MG. Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease. World J Gastroenterol. 2016;22(8):2592-600.

10. Baik M, Kim SU, Kang S, Park HJ, Nam HS, Heo JH, et al. Liver Fibrosis, Not Steatosis, Associates with Long-Term Outcomes in Ischaemic Stroke Patients. Cerebrovasc Dis. 2019;47(1-2):32-9.

11. Baik M, Kim SU, Nam HS, Heo JH, Kim YD. The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke. Front Neurol. 2019;10:375.

12. Chang Y, Cho YK, Cho J, Jung HS, Yun KE, Ahn J, et al. Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study. Am J Gastroenterol. 2019;114(4):620-9.

13. Chang Y, Ryu S, Sung KC, Cho YK, Sung E, Kim HN, et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. Gut. 2019;68(9):1667-75.

14. Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol. 2013;108(12):1861-8.

15. Chang Y, Ryu S, Suh BS, Yun KE, Kim CW, Cho SI. Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men. Int J Obes (Lond). 2012;36(9):1187-94.

16. Chang Y, Jung HS, Yun KE, Cho J, Ahn J, Chung EC, et al. Metabolically healthy obesity is associated with an increased risk of diabetes independently of nonalcoholic fatty liver disease. Obesity (Silver Spring). 2016;24(9):1996-2003.

17. Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53(4):686-92.

18. Chang Y, Ryu S, Sung E, Woo HY, Oh E, Cha K, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008;57(4):569-76.

19. Chang Y, Ryu S, Zhang Y, Son HJ, Kim JY, Cho J, et al. A cohort study of serum bilirubin levels and incident non-alcoholic fatty liver disease in middle aged Korean workers. PLoS One. 2012;7(5):e37241.

20. Chang Y, Ryu S, Sung E, Woo HY, Cho SI, Yoo SH, et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut. 2009;58(10):1419-25.

21. Chang Y, Jung HS, Cho J, et al. Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2016;111(8):1133-1140.

22. Cho HC. Prevalence and Factors Associated with Nonalcoholic Fatty Liver Disease in a Nonobese Korean Population. Gut Liver. 2016;10(1):117-25.

23. Cho HJ, Hwang S, Park JI, Yang MJ, Hwang JC, Yoo BM, et al. Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus. Gut Liver. 2019;13(4):440-9.

24. Cho SH, Hahm SK, Seo YN, Kim KU, Kim JY, Park JA. The Association of Non-alcoholic Fatty Liver Disease and Physical Activity. J Korean Acad Fam Med. 2008;29(7):513-9.

25. Choe EY, Lee YH, Choi YJ, Huh BW, Lee BW, Kim SK, et al. Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes. J Gastroenterol Hepatol. 2018;33(5):1082-91.

26. Choe YG, Jin W, Cho YK, Chung WG, Kim HJ, Jeon WK, et al. Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects. J Gastroenterol Hepatol. 2013;28(4):678-83.

27. Choi JH, Rhee EJ, Bae JC, Park SE, Park CY, Cho YK, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res. 2013;44(2):115-20.

28. Choi SY, Kim D, Kim HJ, Kang JH, Chung SJ, Park MJ, et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol. 2009;104(8):1953-60.

29. Choi WG, Kim SJ, Myung SJ, Choi SO, Kim JH, Park SW, et al. Associations between Nonalcoholic Fatty Liver Disease and Colorectal Adenoma in Health Screen Examinees. Korean J Gastrointest Endosc. 2010;41(4):201-7.

30. Choi Y, Lee JE, Chang Y, Kim MK, Sung E, Shin H, et al. Dietary sodium and potassium intake in relation to non-alcoholic fatty liver disease. Br J Nutr. 2016;116(8):1447-56.

31. Chon CW, Kim BS, Cho YK, Sung KC, Bae JC, Kim TW, et al. Effect of nonalcoholic Fatty liver disease on the development of type 2 diabetes in nonobese, nondiabetic korean men. Gut Liver. 2012;6(3):368-73.

32. Chon YE, Kim KJ, Jung KS, Kim SU, Park JY, Kim do Y, et al. The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. Yonsei Med J. 2016;57(4):885-92.

33. Chung GE, Youn J, Kim YS, Lee JE, Yang SY, Lim JH, et al. Dietary patterns are associated with the prevalence of nonalcoholic fatty liver disease in Korean adults. Nutrition. 2019;62:32-8.

34. Chung GE, Lee Y, Yim JY, Choe EK, Kwak MS, Yang JI, et al. Genetic Polymorphisms of PNPLA3 and SAMM50 Are Associated with Nonalcoholic Fatty Liver Disease in a Korean Population. Gut Liver. 2018;12(3):316-23.

35. Chung GE, Yim JY, Kim D, Lim SH, Yang JI, Kim YS, et al. The Influence of Metabolic Factors for Nonalcoholic Fatty Liver Disease in Women. BioMed Research International. 2015;2015:1-8.

36. Chung GE, Lee JH, Lee H, Kim MK, Yim JY, Choi SY, et al. Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. Atherosclerosis. 2018;272:137-44.

37. Chung GE, Choi SY, Kim D, Kwak MS, Park HE, Kim MK, et al. Nonalcoholic fatty liver disease as a risk factor of arterial stiffness measured by the cardioankle vascular index. Medicine (Baltimore). 2015;94(12):e654.

38. Chung GE, Yim JY, Kim D, Kwak MS, Yang JI, Chung SJ, et al. Associations between hemoglobin concentrations and the development of incidental metabolic syndrome or nonalcoholic fatty liver disease. Dig Liver Dis. 2017;49(1):57-62.

39. Huh JH, Ahn SV, Koh SB, Choi E, Kim JY, Sung KC, et al. A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study. PLoS One. 2015;10(11):e0143560.

40. Huh JH, Lee KJ, Lim JS, Lee MY, Park HJ, Kim MY, et al. High Dietary Sodium Intake Assessed by Estimated 24-h Urinary Sodium Excretion Is Associated with NAFLD and Hepatic Fibrosis. PLoS One. 2015;10(11):e0143222.

41. Huh JH, Kim KJ, Kim SU, Han SH, Han KH, Cha BS, et al. Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. Metabolism. 2017;66:23-31.

42. Huh JH, Kim JY, Choi E, Kim JS, Chang Y, Sung KC. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. PLoS One. 2017;12(7):e0180951.

43. Hwang ST, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol. 2010;25(3):562-7.

44. Hwang YC, Ahn HY, Park SW, Park CY. Nonalcoholic Fatty Liver Disease Associates With Increased Overall Mortality and Death From Cancer, Cardiovascular Disease, and Liver Disease in Women but Not Men. Clin Gastroenterol Hepatol. 2018;16(7):1131-7 e5.

45. Jang EH, Chang Y, Ryu S, Kim S, Kim YH, Sung KC, et al. Cardiovascular Health Metrics in the Development and Regression of Nonalcoholic Fatty Liver Disease: A Cohort Study. J Clin Med. 2019;8(5).

46. Jang H, Kang D, Chang Y, Kim Y, Lee JS, Kim KW, et al. Non-alcoholic fatty liver disease and cerebral small vessel disease in Korean cognitively normal individuals. Sci Rep. 2019;9(1):1814.

47. Jang HR, Kang D, Sinn DH, Gu S, Cho SJ, Lee JE, et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep. 2018;8(1):4718.

48. Jeong EH, Jun DW, Cho YK, Choe YG, Ryu S, Lee SM, et al. Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. Clin Mol Hepatol. 2013;19(3):266-72.

49. Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study. Hepatology. 2017;65(3):828-35.

50. Jun DW, Han JH, Kim SH, Jang EC, Kim NI, Lee JS, et al. Association between low thigh fat and non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2008;23(6):888-93.

51. Jun DW, Kim SG, Park SH, Jin SY, Lee JS, Lee JW, et al. External validation of the non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients. J Gastroenterol Hepatol. 2017;32(5):1094-9.

52. Jun EJ, Kim HS, Chung HK, Lee JH, Kim SR, Jung ED. Free T4 is Negatively Correlated with Non-alcoholic Fatty Liver Disease in Euthyroid Women. J Korean Endocr Soc. 2009;24(2):87-92.

53. Jun MJ, Shim JH, Kim SY, Seo N, Kim KM, Lim YS, et al. Clinical implications of preoperative and intraoperative liver biopsies for evaluating donor steatosis in living related liver transplantation. Liver Transpl. 2014;20(4):437-45.

54. Jung CH, Lee WJ, Hwang JY, Yu JH, Shin MS, Lee MJ, et al. Assessment of the fatty liver index as an indicator of hepatic steatosis for predicting incident diabetes independently of insulin resistance in a Korean population. Diabet Med. 2013;30(4):428-35.

55. Jung CH, Kang YM, Jang JE, Hwang JY, Kim EH, Park JY, et al. Fatty liver index is a risk determinant of incident type 2 diabetes in a metabolically healthy population with obesity. Obesity (Silver Spring). 2016;24(6):1373-9.

56. Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, et al. Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study. Am J Gastroenterol. 2019;114(3):453-63.

57. Jung JY, Park SK, Ryoo JH, Oh CM, Kang JG, Lee JH, et al. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. Hepatol Res. 2017;47(6):522-32.

58. Kang MK, Kang BH, Kim JH. Nonalcoholic Fatty Liver Disease Is Associated with the Presence and Morphology of Subclinical Coronary Atherosclerosis. Yonsei Med J. 2015;56(5):1288-95.

59. Kang YM, Jung CH, Cho YK, Lee SE, Lee MJ, Hwang JY, et al. Fatty liver disease determines the progression of coronary artery calcification in a metabolically healthy obese population. PLoS One. 2017;12(4):e0175762.

60. Keum SH, Lee KM, Jung SP. Nonalcoholic Fatty Liver Disease as a Risk Factor for Cardiovascular Disease: Using the Estimation of Framingham Risk Score and Carotid Artherosclerosis. Korean J Health Promot. 2012;12(4):163-9.

61. Khang AR, Lee HW, Yi D, Kang YH, Son SM. The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea National Health and Nutrition Examination Survey 2010-2011. Diabetes Metab Syndr Obes. 2019;12:181-90.

62. Kim BJ, Kim HS, Kang JG, Kim BS, Kang JH. Association of epicardial fat volume and nonalcoholic fatty liver disease with metabolic syndrome: From the CAESAR study. J Clin Lipidol. 2016;10(6):1423-30 e1.

63. Kim CW, Yun KE, Jung HS, Chang Y, Choi ES, Kwon MJ, et al. Sleep duration and quality in relation to non-alcoholic fatty liver disease in middle-aged workers and their spouses. J Hepatol. 2013;59(2):351-7.

64. Kim CW, Chang Y, Sung E, Shin H, Ryu S. Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism. 2012;61(8):1182-8.

65. Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology. 2012;56(2):605-13.

66. Kim D, Chung GE, Kwak MS, Seo HB, Kang JH, Kim W, et al. Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016;14(1):132-8 e4.

67. Kim D, Chung GE, Kwak MS, Kim YJ, Yoon JH. Effect of longitudinal changes of body fat on the incidence and regression of nonalcoholic fatty liver disease. Dig Liver Dis. 2018;50(4):389-95.

68. Kim G, Lee SE, Lee YB, Jun JE, Ahn J, Bae JC, et al. Relationship between relative skeletal muscle mass and non-alcoholic fatty liver disease: A 7-year longitudinal study. Hepatology. 2018.

69. Kim G, Kim KJ, Rhee Y, Lim SK. Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease. PLoS One. 2017;12(7):e0182202.

70. Kim GA, Lee HC, Choe J, Kim MJ, Lee MJ, Chang HS, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2017.

71. Kim HJ, Kim DJ, Kim SK, Kim SH, Rhee YM, Ahn CW, et al. Metabolic Abnormalities according to Severity of Non-alcoholic Fatty Liver Disease in Korean Adults. J Korean Soc Endocrinol. 2002;17(4):514-25.

72. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Archives of internal medicine. 2004;164(19):2169-75.

73. Kim HK, Suh CJ, Yoon HJ, Hwang YH, Lee KY, Park HY, et al. Association between Non-alcoholic Fatty Liver and Metabolic Diseases. J Korean Soc Endocrinol. 2002;17(4):526-34.

74. Kim HK, Park JY, Lee KU, Lee GE, Jeon SH, Kim JH, et al. Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. Am J Med Sci. 2009;337(2):98-102.

75. Kim H-L, Chung GE, Park IY, Choi JM, Hwang S-M, Lee J-H, et al. Elevated Peripheral Blood Monocyte Fraction in Nonalcoholic Fatty Liver Disease. The Tohoku Journal of Experimental Medicine. 2011;223(3):227-33.

76. Kim HY, Kim CW, Park C-H, Choi JY, Han K, Merchant AT, et al. Low skeletal muscle mass is associated with non-alcoholic fatty liver disease in Korean adults: the Fifth Korea National Health and Nutrition Examination Survey. Hepatobiliary & Pancreatic Diseases International. 2016;15(1):39-47.

77. Kim J, Lee DY, Park SE, Park CY, Lee WY, Oh KW, et al. Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation. PLoS One. 2017;12(7):e0180118.

78. Kim JH, Jung DH, Kwon YJ, Lee JI, Shim JY. The impact of the sleep duration on NAFLD score in Korean middle-aged adults: a community-based cohort study. Sleep Med. 2019;57:144-50.

79. Kim JK, Chon NR, Lim HC, Lee KS, Han KH, Chon CY, et al. Transitional features of histologic type of non-alcoholic fatty liver disease in Korean young men. J Gastroenterol Hepatol. 2012;27(1):142-8.

80. Kim JM, Ha SY, Joh JW, Sinn DH, Jeong WK, Choi GS, et al. Predicting Hepatic Steatosis in Living Liver Donors via Noninvasive Methods. Medicine (Baltimore). 2016;95(7):e2718.

81. Kim JY, Lee C, Oh M, Im JA, Lee JW, Chu SH, et al. Relationship between non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance in Korean adults: A cross-sectional study. Clin Chim Acta. 2016;458:12-7.

82. Jin YJ, Kim KM, Hwang S, et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors. J Gastroenterol Hepatol. 2012;27(8):1341‐1347.

83. Kim MK, Ahn CW, Nam JS, Kang S, Park JS, Kim KR. Association between nonalcoholic fatty liver disease and coronary artery calcification in postmenopausal women. Menopause. 2015;22(12):1323-7.

84. Kim NH, Jung YS, Hong HP, Park JH, Kim HJ, Park DI, et al. Association between cotinine-verified smoking status and risk of nonalcoholic fatty liver disease. Liver International. 2018.

85. Kim NH, Kim JH, Kim YJ, Yoo HJ, Kim HY, Seo JA, et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int. 2014;34(4):604-11.

86. Kim S, Chang Y, Sung E, Kim CH, Yun KE, Jung HS, et al. Non-alcoholic fatty liver disease and the development of nephrolithiasis: A cohort study. PLoS One. 2017;12(10):e0184506.

87. Kim S, Choi J, Kim M. Insulin resistance, inflammation, and nonalcoholic fatty liver disease in non-obese adults without metabolic syndrome components. Hepatol Int. 2013;7(2):586-91.

88. Kim SH, Lee JW, Hwang HJ. Associations between combinations of body mass index plus non-alcoholic fatty liver disease and diabetes mellitus among Korean adults. Asia Pacific journal of clinical nutrition. 2011;20(1):14-20.

89. Kim NH, Park J, Kim SH, et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart. 2014;100(12):938‐943.

90. Kim SM, Kim JA, Han JH, Cho KH, Yoon D. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome in Nonobese, Nondiabetic Adults. Korean J Obes. 2006;15(1):44-51.

91. Kim SS, Cho HJ, Kim HJ, Kang DR, Berry JR, Kim JH, et al. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Dig Liver Dis. 2018;50(4):370-7.

92. Kim SY, Shim KW, Lee HS, Lee SH, Kim HL, Oh YA. The Association of Nonalcoholic Fatty Liver Disease with Metabolic Syndrome. J Korean Acad Fam Med. 2007;28(9):667-74.

93. Kim TJ, Sinn DH, Min YW, Son HJ, Kim JJ, Chang Y, et al. A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease. J Gastroenterol. 2017;52(11):1201-10.

94. Kim YC, Cho YK, Lee WY, Kim HJ, Park JH, Park DI, et al. Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects. J Nutr Biochem. 2011;22(3):289-92.

95. Kim YS, Jung ES, Hur W, Bae SH, Choi JY, Song MJ, et al. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol. 2013;19(2):120-30.

96. Koo BK, Joo SK, Kim D, Bae JM, Park JH, Kim JH, et al. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2018;33(6):1277-85.

97. Kwak MS, Kim D, Chung GE, Kim W, Kim YJ, Yoon JH. Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance. Liver Int. 2015;35(3):944-52.

98. Kwak MS, Kim KW, Seo H, Chung GE, Yim JY, Kim D. Non-obese fatty liver disease is associated with lacunar infarct. Liver Int. 2018;38(7):1292-9.

99. Kwak MS, Yim JY, Kim D, Park MJ, Lim SH, Yang JI, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcium score in diabetes patients with higher HbA1c. Diabetol Metab Syndr. 2015;7:28.

100. Kwak MS, Kim E, Jang EJ, Lee CH. The association of non-alcoholic fatty liver disease with lung function: A survey design analysis using propensity score. Respirology. 2018;23(1):82-8.

101. Kwak MS, Kim D, Chung GE, Kim W, Kim YJ, Yoon JH. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol. 2015;21(20):6287-95.

102. Kwon YM, Oh SW, Hwang SS, Lee C, Kwon H, Chung GE. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol. 2012;107(12):1852-8.

103. Lee H, Kim G, Choi YJ, Huh BW, Lee BW, Kang ES, et al. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. Diabetes Metab J. 2019.

104. Lee HW, Park SY, Kim SU, Jang JY, Park H, Kim JK, et al. Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. PLoS One. 2016;11(6):e0157358.

105. Lee HW, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, et al. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2017;62(8):2150-8.

106. Lee HW, Kim KJ, Jung KS, Chon YE, Huh JH, Park KH, et al. The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. PLoS One. 2017;12(10):e0187066.

107. Lee J, Yoon K, Ryu S, Chang Y, Kim HR. High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men. PLoS One. 2017;12(2):e0172666.

108. Lee JA, Lee SH, Son JW, Kim J, Oh YS, Shinn SH. Association of Non-alcoholic Fatty Liver Disease with Insulin Resistance in Non-Diabetic, Normal Weight Adults. Korean J Med. 2004;67(5):506-12.

109. Lee JE, Lee YJ, Chung SY, Cho HW, Park BJ, Jung DH. Severity of nonalcoholic fatty liver disease is associated with subclinical cerebro-cardiovascular atherosclerosis risk in Korean men. PLoS One. 2018;13(3):e0193191.

110. Lee JI, Kim MC, Moon BS, Song YS, Han EN, Lee HS, et al. The Relationship between 10-Year Cardiovascular Risk Calculated Using the Pooled Cohort Equation and the Severity of Non-Alcoholic Fatty Liver Disease. Endocrinol Metab (Seoul). 2016;31(1):86-92.

111. Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol. 2007;47(2):239-44.

112. Lee K, Sung JA, Kim JS, Park TJ. The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans. Diabetes Metab Res Rev. 2009;25(2):150-5.

113. Lee KE, Kim YM, Kang ES, Kim HJ, Chung HW, Lee SH, et al. Metabolic significance of non-alcoholic fatty liver disease in non-obese adults. Korean J Med. 2002;63(5):488-95.

114. Lee KW, Bang KB, Rhee EJ, Kwon HJ, Lee MY, Cho YK. Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study. Clin Mol Hepatol. 2015;21(4):372-8.

115. Lee MJ, Kim EH, Bae SJ, Kim GA, Park SW, Choe J, et al. Age-Related Decrease in Skeletal Muscle Mass Is an Independent Risk Factor for Incident Nonalcoholic Fatty Liver Disease: A 10-Year Retrospective Cohort Study. Gut Liver. 2019;13(1):67-76.

116. Lee MK, Park HJ, Jeon WS, Park SE, Park CY, Lee WY, et al. Higher association of coronary artery calcification with non-alcoholic fatty liver disease than with abdominal obesity in middle-aged Korean men: the Kangbuk Samsung Health Study. Cardiovasc Diabetol. 2015;14:88.

117. Lee S, Ko BJ, Gong Y, Han K, Lee A, Han BD, et al. Self-reported eating speed in relation to non-alcoholic fatty liver disease in adults. Eur J Nutr. 2016;55(1):327-33.

118. Lee SB, Park GM, Lee JY, Lee BU, Park JH, Kim BG, et al. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study. J Hepatol. 2018;68(5):1018-24.

119. Lee SY, Kim SK, Kwon CI, Kim MJ, Kang MS, Ko KH, et al. Clinical characteristics of health screen examinees with nonalcoholic fatty liver and normal liver function test. Korean J Gastroenterol. 2008;52(3):161-70.

120. Lee T, Yun KE, Chang Y, Ryu S, Park DI, Choi K, et al. Risk of Colorectal Neoplasia According to Fatty Liver Severity and Presence of Gall Bladder Polyps. Dig Dis Sci. 2016;61(1):317-24.

121. Lee, M.K., et al., Metabolic Health Is More Important than Obesity in the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Retrospective Study. Endocrinol Metab (Seoul), 2015. 30(4): p. 522-30.

122. Lee YH, Bang H, Park YM, Bae JC, Lee BW, Kang ES, et al. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One. 2014;9(9):e107584.

123. Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). J Hepatol. 2015;63(2):486-93.

124. Lee YH, Kim SU, Song K, Park JY, Kim DY, Ahn SH, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). Hepatology. 2016;63(3):776-86.

125. Lee YI, Lim YS, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol. 2012;27(1):91-5.

126. Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med. 2010;48(2):175-80.

127. Min YW, Yun HS, Chang WI, Kim JY, Kim YH, Son HJ, et al. Influence of non-alcoholic fatty liver disease on the prognosis in patients with colorectal cancer. Clin Res Hepatol Gastroenterol. 2012;36(1):78-83.

128. Moon JS, Yoon JS, Won KC, Lee HW. The Role of Skeletal Muscle in Development of Nonalcoholic Fatty Liver Disease. Diabetes & Metabolism Journal. 2013;37(4).

129. Nah EH, Park JY. Metabolic Characteristics and Associated Factors of Nonalcoholic Fatty Liver Disease Diagnosed at Medical Checkups. Korean J Lab Med. 2008;28(3):244-50.

130. Nam JS, Jo S, Kang S, Ahn CW, Kim KR, Park JS. Association between lipoprotein(a) and nonalcoholic fatty liver disease among Korean adults. Clin Chim Acta. 2016;461:14-8.

131. Oh SY, Cho YK, Kang MS, Yoo TW, Park JH, Kim HJ, et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism. 2006;55(12):1604-9.

132. Park BJ, Kim YJ, Kim DH, Kim W, Jung YJ, Yoon JH, et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol. 2008;23(6):900-7.

133. Park D, Kwon H, Oh SW, Joh HK, Hwang SS, Park JH, et al. Is Vitamin D an Independent Risk Factor of Nonalcoholic Fatty Liver Disease?: a Cross-Sectional Study of the Healthy Population. J Korean Med Sci. 2017;32(1):95-101.

134. Park HE, Kwak MS, Kim D, Kim MK, Cha MJ, Choi SY. Nonalcoholic Fatty Liver Disease Is Associated With Coronary Artery Calcification Development: A Longitudinal Study. J Clin Endocrinol Metab. 2016;101(8):3134-43.

135. Park JH, Cho B, Kwon H, Prilutsky D, Yun JM, Choi HC, et al. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver Int. 2015;35(12):2537-46.

136. Park JM, Lee HS, Oh J, Lee YJ. Serum Testosterone Level Within Normal Range Is Positively Associated with Nonalcoholic Fatty Liver Disease in Premenopausal but Not Postmenopausal Women. J Womens Health (Larchmt). 2019.

137. Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol. 2007;22(4):491-7.

138. Park KS, Lee YS, Park HW, Seo SH, Jang BG, Hwang JY, et al. Factors associated or related to with pathological severity of nonalcoholic fatty liver disease. The Korean journal of internal medicine. 2004;19(1):19-26.

139. Park SH, Kim BI, Yoo TW, Kim JW, Cho YK, Sung IK, et al. Nonalcoholic Fatty Liver Disease and Abnormal Liver Function Test in the Health Screen Examinees: the Relationship with Insulin Resistance. Korean J Gastroenterol. 2003;41(5):366-73.

140. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006;21(1 Pt 1):138-43.

141. Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013;57(4):1378-83.

142. Rhee EJ, Lee WY, Cho YK, Kim BI, Sung KC. Hyperinsulinemia and the development of nonalcoholic Fatty liver disease in nondiabetic adults. Am J Med. 2011;124(1):69-76.

143. Rhee EJ, Kim MK, Park SE, Park CY, Baek KH, Lee WY, et al. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocrine journal. 2013;60(6):743-52.

144. Ryoo JH, Ham WT, Choi JM, Kang MA, An SH, Lee JK, et al. Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension. J Korean Med Sci. 2014;29(7):973-9.

145. Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014;29(11):1926-31.

146. Ryoo JH, Choi JM, Moon SY, Suh YJ, Shin JY, Shin HC, et al. The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-year's prospective cohort study. Atherosclerosis. 2013;227(2):398-403.

147. Ryoo JH, Hong HP, Park SK, Ham WT, Chung JY. The Risk for Insulin Resistance according to the Degree of Non-Alcoholic Fatty Liver Disease in Korean Men. J Korean Med Sci. 2016;31(11):1761-7.

148. Ryu S, Chang Y, Jung HS, Yun KE, Kwon MJ, Choi Y, et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J Hepatol. 2015;63(5):1229-37.

149. Ryu S, Suh BS, Chang Y, Kwon MJ, Yun KE, Jung HS, et al. Menopausal stages and non-alcoholic fatty liver disease in middle-aged women. Eur J Obstet Gynecol Reprod Biol. 2015;190:65-70.

150. Ryu S, Chang Y, Kim SG, Cho J, Guallar E. Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism. 2011;60(6):860-6.

151. Seo HI, Cho YK, Lee WY, Rhee EJ, Sung KC, Kim BS, et al. Which metabolic syndrome criteria best predict the presence of non-alcoholic fatty liver disease? Diabetes Res Clin Pract. 2012;95(1):19-24.

152. Seo NK, Koo HS, Haam JH, Kim HY, Kim MJ, Park KC, et al. Prediction of prevalent but not incident non-alcoholic fatty liver disease by levels of serum testosterone. J Gastroenterol Hepatol. 2015;30(7):1211-6.

153. Seo SH, Lee HW, Park HW, Jang BG, Chung WJ, Park KS, et al. Prevalence and associated factors of nonalcoholic fatty liver disease in the health screen examinees. Korean J Med. 2006;70(1):26-32.

154. Seo YY, Cho YK, Bae JC, Seo MH, Park SE, Rhee EJ, et al. Tumor Necrosis Factor-alpha as a Predictor for the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Follow-Up Study. Endocrinol Metab (Seoul). 2013;28(1):41-5.

155. Shin JY, Kim MJ, Kim ES, Mo EY, Moon SD, Han JH, et al. Association between serum calcium and phosphorus concentrations with non-alcoholic fatty liver disease in Korean population. J Gastroenterol Hepatol. 2015;30(4):733-41.

156. Shin WY, Jung DH, Shim JY, Lee HR. The association between non-alcoholic hepatic steatosis and mean platelet volume in an obese Korean population. Platelets. 2011;22(6):442-6.

157. Sinn DH, Gwak GY, Rhee SY, Cho J, Son HJ, Paik YH, et al. Association between serum osteocalcin levels and non-alcoholic fatty liver disease in women. Digestion. 2015;91(2):150-7.

158. Sinn DH, Kang D, Jang HR, Gu S, Cho SJ, Paik SW, et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. J Hepatol. 2017;67(6):1274-80.

159. Sinn DH, Kang D, Chang Y, Ryu S, Gu S, Kim H, et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut. 2017;66(2):323-9.

160. Sinn DH, Cho SJ, Gwak GY, Cho J, Gu S, Seong D, et al. Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis. Medicine (Baltimore). 2016;95(3):e2578.

161. Sinn DH, Cho SJ, Gu S, Seong D, Kang D, Kim H, et al. Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis. Gastroenterology. 2016;151(3):481-8 e1.

162. Sinn DH, Gwak GY, Park HN, Kim JE, Min YW, Kim KM, et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastroenterol. 2012;107(4):561-7.

163. Song DS, Chang UI, Kang SG, Song SW, Yang JM. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease. Gut Liver. 2019.

164. Song JU, Jang Y, Lim SY, Ryu S, Song WJ, Byrne CD, et al. Decreased lung function is associated with risk of developing non-alcoholic fatty liver disease: A longitudinal cohort study. PLoS One. 2019;14(1):e0208736.

165. Song YA, Kwon SS, Doo SW, Kim JH, Yang WJ, Song YS. Is There Any Relation Between the Degree of Fatty Liver Disease and Severity of Lower Urinary Tract Symptoms? Urology. 2016;89:90-5.

166. Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012;35(4):717-22.

167. Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol. 2014;60(5):1040-5.

168. Sung KC, Ryu S, Lee JY, Lee SH, Cheong ES, Wild SH, et al. Fatty Liver, Insulin Resistance, and Obesity: Relationships With Increase in Coronary Artery Calcium Over Time. Clin Cardiol. 2016;39(6):321-8.

169. Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care. 2012;35(11):2359-64.

170. Sung KC, Ryu S, Lee JY, Kim JY, Wild SH, Byrne CD. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. J Hepatol. 2016;65(4):791-7.

171. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab. 2011;96(4):1093-7.

172. Sung KC, Cha SC, Sung JW, So MS, Byrne CD. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. Nutr Metab Cardiovasc Dis. 2014;24(3):256-62.

173. Sung KC, Lee MY, Kim YH, Huh JH, Kim JY, Wild SH, et al. Obesity and incidence of diabetes: Effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver. Atherosclerosis. 2018;275:50-7.

174. Sung KC, Ryan MC, Kim BS, Cho YK, Kim BI, Reaven GM. Relationships between estimates of adiposity, insulin resistance, and nonalcoholic fatty liver disease in a large group of nondiabetic Korean adults. Diabetes Care. 2007;30(8):2113-8.

175. Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013;98(9):3637-43.

176. Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis. 2009;203(2):581-6.

177. Sung KC, Lee MY, Lee JY, Lee SH, Kim SH, Kim SH. Utility of ALT Concentration in Men and Women with Nonalcoholic Fatty Liver Disease: Cohort Study. J Clin Med. 2019;8(4).

178. Sung KC, Kim BS, Cho YK, Park DI, Woo S, Kim S, et al. Predicting incident fatty liver using simple cardio-metabolic risk factors at baseline. BMC gastroenterology. 2012;12:84.

179. Yadav D, Choi E, Ahn SV, Koh SB, Sung KC, Kim JY, et al. Fatty liver index as a simple predictor of incident diabetes from the KoGES-ARIRANG study. Medicine (Baltimore). 2016;95(31):e4447.

180. Yang HJ, Chang Y, Park SK, Jung YS, Park JH, Park DI, et al. Nonalcoholic Fatty Liver Disease Is Associated with Increased Risk of Reflux Esophagitis. Dig Dis Sci. 2017;62(12):3605-13.

181. Yang MH, Sung J, Gwak GY. The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. J Clin Lipidol. 2016;10(2):289-98.

182. Yang YJ, Bang CS, Shin SP, Baik GH. Clinical impact of non-alcoholic fatty liver disease on the occurrence of colorectal neoplasm: Propensity score matching analysis. PLoS One. 2017;12(8):e0182014.

183. Yeo J, Kim KK, Hwang IC. Association between the Severity of Nonalcoholic Fatty Liver Disease and High Sensitivity C-reactive Protein in Adults. Korean J Obes. 2012;21(3):166-74.

184. Yi KH, Hwang JS, Lim SW, Lee JA, Kim DH, Lim JS. Early menarche is associated with non-alcoholic fatty liver disease in adulthood. Pediatr Int. 2017;59(12):1270-5.

185. Yoo JH, Kang YM, Cho YK, Lee J, Jung CH, Park JY, et al. The haemoglobin glycation index is associated with nonalcoholic fatty liver disease in healthy subjects. Clin Endocrinol (Oxf). 2019;91(2):271-7.

186. You SC, Kim KJ, Kim SU, Kim BK, Park JY, Kim DY, et al. Factors associated with significant liver fibrosis assessed using transient elastography in general population. World J Gastroenterol. 2015;21(4):1158-66.

187. You SC, Kim KJ, Kim SU, Kim BK, Park JY, Kim DY, et al. Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. J Gastroenterol Hepatol. 2015;30(10):1536-42.

188. Yu SJ, Kim W, Kim D, Yoon JH, Lee K, Kim JH, et al. Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Medicine (Baltimore). 2015;94(48):e2159.

189. Yun KE, Nam GE, Lim J, Park HS, Chang Y, Jung HS, et al. Waist Gain Is Associated with a Higher Incidence of Nonalcoholic Fatty Liver Disease in Korean Adults: A Cohort Study. PLoS One. 2016;11(7):e0158710.

190. Yun Y, Kim HN, Lee EJ, Ryu S, Chang Y, Shin H, et al. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects. PLoS One. 2019;14(3):e0213692.

191. Ze EY, Kim BJ, Jun DH, Kim JG, Kang H, Lee DY. The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population. Dis Colon Rectum. 2018;61(1):36-42.